Versant Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$907 Hold
27
– – ﹤0.01% 2719
2026
Q2
$1.12K Hold
27
– – ﹤0.01% 2629
2026
Q1
$845 Buy
+27
New +$759 ﹤0.01% 2671

Other funds holding RAPP

Versant Capital Management's RAPP Position: Q3 2026 in Review

Versant Capital Management held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 27 shares worth $907. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

Versant Capital Management first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.12K in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Versant Capital Management held 27 shares of Rapport Therapeutics worth $907 as of Q3 2026.
  • Versant Capital Management left its Rapport Therapeutics share count unchanged in Q3 2026.
  • Rapport Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2719 holding.
  • Versant Capital Management first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Versant Capital Management's Rapport Therapeutics position peaked at $1.12K in Q2 2026.
  • 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.